Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 274, Issue 1-2, 2014, Pages 96-101

  Lee, De Hyung ^a   Rötger, Caroline ^a   Appeldoorn, Chantal C M ^b   Reijerkerk, Arie ^b   Gladdines, Werner ^b   Gaillard, Pieter J ^b   Linker, Ralf A ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b to BBB Technologies BV   (Netherlands)

Author keywords

Axonal injury; EAE; Liposome; Neurodegeneration; Relapse treatment; Steroid

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOCORTICOID; GLUTATHIONE PEGYLATED LIPOSOMAL METHYLPREDNISOLONE SODIUM SUCCINATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMYELINATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MACROPHAGE; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPINAL CORD; T LYMPHOCYTE;

AXONAL INJURY; EAE; LIPOSOME; NEURODEGENERATION; RELAPSE TREATMENT; STEROID;

ANIMALS; ASTROCYTES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; LIPOSOMES; MACROPHAGES; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; POLYETHYLENE GLYCOLS; SPINAL CORD; T-LYMPHOCYTES;

EID: 84906935393     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.06.025     Document Type: Article

References (24)

1. Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 2013, 10:97-105.
2. Brusaferri F., Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J. Neurol. 2000, 247:435-442.
3. Gaillard P.J., Appeldoorn C.C., Rip J., Dorland R., van der Pol S.M., Kooij G., et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J. Control. Release 2012, 164:364-369.
4. Gaillard P.J., Appeldoorn C., Dorland R., van Kregten J., Manca F., Vugts D., et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 2014, 9(1):e82331.
5. Gold R., Buttgereit F., Toyka K.V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J. Neuroimmunol. 2001, 117:1-8.
6. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
7. Grauer O., Offenhausser M., Schmidt J., Toyka K.V., Gold R. Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations. Nervenarzt 2001, 72:577-589.
8. Herrero-Herranz E., Pardo L.A., Gold R., Linker R.A. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol. Dis. 2008, 30:162-173.
9. Hirst C., Ingram G., Pearson O., Pickersgill T., Scolding N., Robertson N. Contribution of relapses to disability in multiple sclerosis. J. Neurol. 2008, 255:280-287.
10. Hofkens W., Grevers L.C., Walgreen B., de Vries T.J., Leenen P.J., Everts V., et al. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. J. Control. Release 2011, 152:363-369.
11. Hofkens W., Storm G., van den Berg W.B., van Lent P.L. Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritis. Int. J. Pharm. 2011, 416:486-492.
12. Lee D.H., Kubera K., Rosenthal B., Kaltschmidt B., Kaltschmidt C., Gold R., et al. Neuronal NF-kappaB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination. J. Neuroimmunol. 2012, 246:38-42.
13. Linker R.A., Maurer M., Gaupp S., Martini R., Holtmann B., Giess R., et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 2002, 8:620-624.
14. Linker R.A., Weller C., Luhder F., Mohr A., Schmidt J., Knauth M., et al. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp. Neurol. 2008, 211:397-406.
15. Linker R.A., Lee D.H., Demir S., Wiese S., Kruse N., Siglienti I., et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010, 133:2248-2263.
16. Metselaar J.M., Storm G. Liposomes in the treatment of inflammatory disorders. Expert Opin. Drug Deliv. 2005, 2:465-476.
17. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
18. Oliveri R.L., Valentino P., Russo C., Sibilia G., Aguglia U., Bono F., et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998, 50:1833-1836.
19. Rauchhaus U., Kinne R.W., Pohlers D., Wiegand S., Wolfert A., Gajda M., et al. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann. Rheum. Dis. 2009, 68:1933-1934.
20. Reijerkerk A., Appeldoorn C.C., Rip J., de Boer M., Gaillard P.J. Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation. Invest. Ophthalmol. Vis. Sci. 2014, 55:2788-2794.
21. Schmidt J., Gold R., Schonrock L., Zettl U.K., Hartung H.P., Toyka K.V. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000, 123(Pt 7):1431-1441.
22. Schmidt J., Metselaar J.M., Wauben M.H., Toyka K.V., Storm G., Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003, 126:1895-1904.
23. Schweingruber N., Haine A., Tiede K., Karabinskaya A., van den Brandt J., Wust S., et al. Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J. Immunol. 2011, 187:4310-4318.
24. Storch M.K., Stefferl A., Brehm U., Weissert R., Wallstrom E., Kerschensteiner M., et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998, 8:681-694.